Navigation Links
Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
Date:2/11/2008

LAVAL, QC, Feb. 11 /PRNewswire-FirstCall/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces today that on Wednesday, February 13, 2008, Dr. Francesco Bellini, Neurochem's Chairman, President and Chief Executive Officer, and Mr. Gary Schmid, Chief Executive Officer of the new nutraceutical business, will present Neurochem's strategy at the 2008 BIO CEO & Investor Conference to be held at the Waldorf-Astoria, in New York (NY). The presentation will take place at 11:00 A.M. EST, in the West Foyer room.

The live Web cast of Neurochem's presentation (audio and visual) can be accessed at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NRMX&item_id=17. A replay of the presentation will begin one (1) hour after the actual presentation time, and will be available until February 20, 2008. Please access the Web cast approximately 15 minutes before the presentation is scheduled to begin.

About Neurochem

Neurochem Inc. is a global health company focused on the research, development and commercialization of products to provide innovative health solutions to address critical unmet medical needs.

To Contact Neurochem

For additional information on Neurochem and its drug development programs, please call the North American toll-free number 1-877-680-4500 or visit our Web Site at http://www.neurochem.com.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Neurochem Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general condi
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
2. Neurochem to present at JPMorgan Healthcare Conference
3. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
4. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
5. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
6. Neurochem reports results for third quarter of fiscal 2007
7. U.S. Representatives Urge Critical Improvements in Prostate Cancer Detection
8. Covance to Present at UBS Global Healthcare Services Conference
9. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
10. Mark Wylie and Suzy Preston Hoover Bring The Biggest Loser Million Pound Tour, Presented by MSN, to Dadeland Mall
11. Stereotaxis to Present at the Deutsche Bank Small- and Mid-Cap Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2008)...ence Call Scheduled Tuesday, August 5, 2008 at 11:...e-FirstCall/ -- Almost Family, Inc.,(Nasdaq: AFAM...sing,services, announced today that it will report..., 2008 on Tuesday, August 5, 2008, before the,mark... will begin at 11:00 a.m. ET on,August 5, 2008 and...
(Date:7/23/2008)...ON, N.J., July 23 /PRNewswire-USNewswire/ -- The N...lity and Patient Safety has,received a planning gr...dation (RWJF) to develop a proposal for improving ...nt will help determine over the next six months wh...ning Forces for Quality initiative,which is focus...
(Date:7/23/2008)..., China, July 23 /Xinhua-PRNewswire-FirstCall/ -- ...letin Board: GTEC) ("Genesis" or,the "Company"), a...public,of China, held a Board of Directors meeting...appointed to serve on the Board of Directors of th...on Committee were formed., Mr. Michael Marks was ...
(Date:7/23/2008)...ERSBURG, Fla., July 23 /PRNewswire/ -- Laura Kolkm...gnized health information exchange,consulting firm...hcare,Information and Management Systems Society (...ing Committee., The HIE Steering Committee, which...ng providers, payers, vendors, consultants and lif...
Breaking Medicine News(10 mins):Health News:Almost Family, Inc. to Report Second Quarter 2008 Financial Results 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2
...ncer stem cells, seem to be obstinate, as scientis...o radiation therapy. As a result, they are extreme...uld even increase the growth of these stem cells, ...a, Los Angeles, who are the first to have suggeste...
...ring Testosterones can slow down the progression o...nducted on mice. Testosterone, the primary male se...hormones referred to as androgens. The findings,... The Journal of Neuroscience, provide new insight ...
...nister Anbumani Ramadoss Tuesday said the governme...minorities to help curb the polio outbreak in Indi...in the polio immunisation campaigns in Uttar Prade... growth of the disease in the state this year. "W...
... researchers have issued a warning about 'DNA-diet... tall claims of its ability to confront cancer and...rchers at the Economic and Social Research Council... at the University of Exeter, is the first study o...
Other Medicine News:Health News:Increase Testosterone Levels To Slow Down Alzheimer’ 2
(Date:7/23/2008)... Body Have Greater Concentrations of,Stem Cells, ...swire/ -- Fat removed,from the lower abdomen and i...excellent source of stem cells, with higher stem c...eports a Brazilian-based study in August,s,Plastic...al journal of the,American Society of Plastic Surg...
(Date:7/23/2008)...Call/ -- Dendreon Corporation,(Nasdaq: DNDN ) tod...Monitoring Committee (IDMC) to review in October 2...ing to the Company,s Phase 3 IMPACT (IMmunotherapy... as D9902B) clinical trial,of PROVENGE(R) (sipuleu...active cellular immunotherapy for the treatment of...
(Date:7/22/2008)...wswire-FirstCall/ -- Following a,thorough review t...Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) t...phase 3 study in liver cancer. Progen confirmed,it...folio of compounds and,the company will actively s...ies through Merger & Acquisition activity., The s...
(Date:7/22/2008)...-- Nonin Medical, a leading innovator,of physiolog...has entered,the clinical testing phase with its br...aturation. Today,s most common application for thi...egional blood oxygenation,in the brain -- cerebral...an ongoing clinical study at the,Duke University M...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 1Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 2Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 3Environmental Toxins Radiation May Be Tied to Breast Cancer 14754 4Ancient lemurs little finger poses mystery 2551 1Ancient lemurs little finger poses mystery 2551 2Senior Obama Strategist David Axelrod and Wife Susan to be Honored for Their Decade Long Commitment to Epilepsy Research at NYC Benefit 14750 1Senior Obama Strategist David Axelrod and Wife Susan to be Honored for Their Decade Long Commitment to Epilepsy Research at NYC Benefit 14750 2Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 1Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 2Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 3
GENTAMICIN SULFATE, 1000X
Gentamicin is a selection antibiotic used for selection of a Bac-to-Bac recombinant expression bacmid following transposition. Gentamicin is provided as a solution at a concentration of 50 mg/ml.
1.0% Tryptone, 0.5% yeast extract, 0.5% Sodium Chloride, 1.5% agarose.
1% tryptone, 0.5% yeast extract, 1.0% Sodium Chloride, 1.5% agar.
Medicine Products: